To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Adaptation of Tacrolimus Dose According to CYP3A5 Polymorphism Allows Renal Transplant Patients to Reach Therapeutic Target Range: Presented at TTS URL: http://www.pslgroup.com/dg/228C2A.htm Doctor's Guide August 15, 2008
By Rachel Parratt SYDNEY, Australia -- August 15, 2008 -- Cytochrome P4503A5 (CYP3A5) genotyping enables a higher proportion of patients to be within therapeutic target range for tacrolimus at 10 days post-transplant, according to results from a randomised, multicentre, open-label study presented at the 22nd International Congress of the Transplantation Society (TTS 2008). Eric Thervet, University Paris-Descartes, Paris, France, presented the findings of The Tacrolimus in Renal Transplantation Individualization Trough Pharmacogenetic (TACTIC) study here on behalf of the Speiesser Group on August 13. The study compared the use of tacrolimus standard daily dose or a daily dose according to pharmacogenetics of CYP3A5 after renal transplantation. A total of 280 de novo renal transplant recipients were included. All patients in the study received a biological induction, mycophenolate mofetil, and steroids. Patients were randomised to receive standard-dose tacrolimus 0.20 mg/kg BID (control group) or tacrolimus according to CYP3A5 genotype (adapted group). CYP3A5*1*1 and CYP3A5*1/*3 expressors received tacrolimus 0.025 mg/kg BID, and CYP3A5*3/*3 carriers received tacrolimus 0.15 mg/kg BID. The primary endpoint was the proportion of patients within a therapeutic plasma drug target range of 10 to 15 ng/mL after 6 doses of tacrolimus at day 10. A significantly higher percentage of patients reached therapeutic target range at day 10 in the adapted group (42.15%) compared with the control group (26.40%) (P = .009). Analyses according to genotype demonstrated that a higher proportion of CYP3A5*1*1 (high metabolism) patients were within therapeutic range (mean 14.87 ng/mL) compared with the control group (mean 7.23 ng/mL) (P = .035). A higher proportion of patients with CYP3A5*1/*3 expressors (low metabolism) were also within therapeutic range (14.23 ng/mL) compared with controls (11.82 ng/mL) (P = .26) However, CYP3A5*3/*3 allele patients (absence of metabolism) had lower therapeutic range (mean 13.67 ng/mL) compared with the controls (mean 18.16 ng/mL) (P = .0002). "This is the first study to show that prospective adaptation of tacrolimus daily dose according to CYP3A5 polymorphism allows for a high proportion of patients to reach therapeutic target range," said Thervet. Funding for this study was sponsored by Roche and Astellas. [Presentation title: Prospective Randomized Study of Pharmacogenetic Adaptation of Tacrolimus Treatment After Renal Transplantation. Mini-Oral Session 18WMO18] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.